BioPharma Resources

Drug Trial Radar · NCT05163288

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

53

Planned (sponsor's estimate)

Start

Jun 30, 2022

Primary completion

Jun 12, 2030

Study completion Dec 2030

Sponsor

Lead sponsor
IntraBio IncIndustry
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A pivotal, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Niemann Pick disease type C (NPC). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care. Following this randomized, double-blind, placebo-controlled "Parent Study", an extension phase is conducted for (1) patients who completed the "Parent Study" and (2) patients who are enrolled directly into the Extension Phase. Currently, the Extension Phase provides patients with 3 years of open-label treatment.

Conditions

  • Niemann-Pick Disease, Type C

Interventions

  • N-Acetyl-L-LeucineDrug

    N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

  • PlaceboOther

    Matching Placebo Sachet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Scale for the Assessment and Rating of Ataxia (all jurisdictions except US)Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)
  2. Modified Scale for the Assessment and Rating of Ataxia (US only)Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

Locations

14 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Completed

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia · Active not recruiting

  • First Faculty of Medicine, Charles University Hospital Prague

    Prague, Czechia · Active not recruiting

  • University of Giessen

    Giessen, Germany · Active not recruiting

  • University of Hamburg

    Hamburg, Germany · Completed

  • SphinCS - Institute of Clinical Science in Lysosomal Storage Disorders

    Höchheim, Germany · Active not recruiting

  • Ludwig Maximilian University of Munich

    München, Germany · Not yet recruiting

  • University Hospital Münster

    Münster, Germany · Active not recruiting

  • Amsterdam UMC

    Amsterdam, Netherlands · Recruiting

  • Comenius University in Bratislva

    Bratislava, Slovakia · Active not recruiting

  • University Hospital Bern Inselspital

    Bern, Switzerland · Active not recruiting

  • Great Ormond Street Hospital

    London, United Kingdom · Active not recruiting

  • Royal Free London NHS Foundation Trust

    London, United Kingdom · Active not recruiting

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.